tbuckley/cabot-search huggingface dataset:
Temporal relationship between systemic endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure
Authors: Tasnim Mohaissen, Bartosz Proniewski, Marta Targosz-Korecka, Anna Bar, Agnieszka Kij, Katarzyna Bulat, Aleksandra Wajda, Aneta Blat, Karolina Matyjaszczyk-Gwarda, Marek Grosicki, Anna Tworzydlo, Magdalena Sternak, Kamila Wojnar-Lason, Raquel Rodrigues-Diez, Agata Kubisiak, Ana Briones, Katarzyna M Marzec, Stefan Chlopicki
Journal: Cardiovascular Research (2021)

Endothelial dysfunction (ED) and red blood cell distribution width (RDW) are both prognostic factors in heart failure (HF), but the relationship between them is not clear. In this study, we used a unique mouse model of chronic HF driven by cardiomyocyte-specific overexpression of activated Gαq protein (Tgαq*44 mice) to characterize the relationship between the development of peripheral ED and the occurrence of structural nanomechanical and biochemical changes in red blood cells (RBCs).Systemic ED was detected in vivo in 8-month-old Tgαq*44 mice, as evidenced by impaired acetylcholine-induced vasodilation in the aorta and increased endothelial permeability in the brachiocephalic artery. ED in the aorta was associated with impaired nitric oxide (NO) production in the aorta and diminished systemic NO bioavailability. ED in the aorta was also characterized by increased superoxide and eicosanoid production. In 4- to 6-month-old Tgαq*44 mice, RBC size and membrane composition displayed alterations that did not result in significant changes in their nanomechanical and functional properties. However, 8-month-old Tgαq*44 mice presented greatly accentuated structural and size changes and increased RBC stiffness. In 12-month-old Tgαq*44 mice, the erythropathy was featured by severely altered RBC shape and elasticity, increased RDW, impaired RBC deformability, and increased oxidative stress (gluthatione (GSH)/glutathione disulfide (GSSG) ratio). Moreover, RBCs taken from 12-month-old Tgαq*44 mice, but not from 12-month-old FVB mice, coincubated with aortic rings from FVB mice, induced impaired endothelium-dependent vasodilation and this effect was partially reversed by an arginase inhibitor [2(S)-amino-6-boronohexanoic acid].In the Tgαq*44 murine model of HF, systemic ED accelerates erythropathy and, conversely, erythropathy may contribute to ED. These results suggest that erythropathy may be regarded as a marker and a mediator of systemic ED in HF. RBC arginase and possibly other RBC-mediated mechanisms may represent novel therapeutic targets for systemic ED in HF.
A Human Pleiotropic Multiorgan Condition Caused by Deficient Wnt Secretion
Authors: Guoliang Chai, Emmanuelle Szenker-Ravi, Changuk Chung, Zhen Li, Lu Wang, Muznah Khatoo, Trevor Marshall, Nan Jiang, Xiaoxu Yang, Jennifer McEvoy-Venneri, Valentina Stanley, Paula Anzenberg, Nhi Lang, Vanessa Wazny, Jia Yu, David M. Virshup, Rie Nygaard, Filippo Mancia, Rijad Merdzanic, Maria B.P. Toralles, Paula M.L. Pitanga, Ratna D. Puri, Rebecca Hernan, Wendy K. Chung, Aida M. Bertoli-Avella, Nouriya Al-Sannaa, Maha S. Zaki, Karl Willert, Bruno Reversade, Joseph G. Gleeson
Journal: New England Journal of Medicine (2021)

Structural birth defects occur in approximately 3% of live births; most such defects lack defined genetic or environmental causes. Despite advances in surgical approaches, pharmacologic prevention remains largely out of reach.
Polydopamine Nanosheets Doped Injectable Hydrogel with Nitric Oxide Release and Photothermal Effects for Bacterial Ablation and Wound Healing
Authors: Genhua Liu, Lu Wang, Ye He, Liucan Wang, Zhiwen Deng, Junjie Liu, Dan Peng, Tao Ding, Lu Lu, Yao Ding, Jixi Zhang, Peng Liu, Kaiyong Cai
Journal: Advanced Healthcare Materials (2021)

Abstract The development of wound dressings with combined antibacterial activities and pro‐healing functions has always been an intractable medical task for treating bacterial wound infection. Herein, a novel injectable hybrid hydrogel dressing is developed, which is doped with nitric oxide (NO) donor (N,N’‐di‐sec‐butyl‐N,N’‐dinitroso‐1,4‐phenylenediamine, BNN6) loaded two‐dimensional polydopamine nanosheets (PDA NS). The hydrogel matrix is in situ formed through dynamic Schiff base crosslinking between hydrazide‐modified γ‐polyglutamic acid (γ‐PGA‐ADH) and aldehyde‐terminated Pluronic F127 (F127‐CHO). Under 808 nm irradiation, the embedded PDA NS exhibits outstanding photothermal transform properties (56.1%) and on‐demand NO release. The combination of photothermal and NO gas therapy with a synergistic antibacterial effect works on both Escherichia coli and Staphylococcus aureus in vitro. Furthermore, a full‐thickness skin defect model also demonstrates that the hybrid hydrogel shows outstanding antibacterial properties and effectively accelerates the wound healing process. Overall, this study provides a facile and promising method for the fabrication of PDA NS based multifunctional hydrogel dressing for the application of infectious skin wound healing.
556TiP A phase I study of SGN-STNV, a novel antibody–drug conjugate targeting sialyl-thomsen-nouveau antigen (STn), in adults with advanced solid tumors (SGNSTNV-001)
Authors: N.J. Lakhani, I. Braña, V.K. Chiu, A. Dowlati, E.K. Lee, S.M. McGoldrick, A. Minchom, X. Tian, A. Patnaik
Journal: Annals of Oncology (2021)
1178P Senescence signature affects overall survival in non-small cell lung cancer
Authors: A. Domen, C. Deben, C. Hermans, H. Lambrechts, V. Siozopoulou, P. Pauwels, M. Van De Wiel, A. Janssens, J.M.H. Hendriks, P.E. van Schil, T. Vandamme, H. Prenen, M. Peeters, F. Lardon, A. Wouters
Journal: Annals of Oncology (2021)
1599P Vaccination in the COVID-19 era: Attitudes amongst oncology patients
Authors: S. Horan, C. Murphy, R. Keogh, P. Bredin, N. Cooley, B. Ryan, W. Connolly, L. Treanor, A. Lynch, F.E. Barrett, L. French, D. O'Doherty, L. Judge, S. Hamilton, L. Grogan, P. Morris, B. Hennessy, J. Naidoo, O.S. Breathnach, R.T. O'Dwyer
Journal: Annals of Oncology (2021)
1046P First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)
Authors: Y. Nakamura, K. Namikawa, S. Yoshikawa, Y. Kiniwa, T. Maekawa, O. Yamasaki, T. Isei, S. Matsushita, M. Nomura, Y. Nakai, S. Fukushima, S. Saito, T. Takenouchi, R. Tanaka, H. Kato, A. Otsuka, T. Matsuya, N. Baba, K. Nagase, T. Inozume
Journal: Annals of Oncology (2021)
1053P Tumour mutational burden (TMB) assessment using next generation sequencing (NGS) for the prediction of complete response (CR) to immunotherapy (IO) in metastatic melanoma
Authors: T.G. Humphries, T. Giardina, N. Mesbah Ardakani, M.A. Khattak, T. Meniawy, A. Jacques, E.S. Gray, B. Amanuel, M. Millward
Journal: Annals of Oncology (2021)
US Emergency Department Visits Attributed to Medication Harms, 2017-2019
Authors: Daniel S. Budnitz, Nadine Shehab, Maribeth C. Lovegrove, Andrew I. Geller, Jennifer N. Lind, Daniel A. Pollock
Journal: JAMA (2021)

Assessing the scope of acute medication harms to patients should include both therapeutic and nontherapeutic medication use.
Application of a novel artificial intelligence system in guiding the targeted puncture of a pancreatic mass
Authors: Xiaoyan Wang, Li Tian, Xiaoyu Yu, Zinan Zhang, Ningxin Zhu, Anliu Tang, Shan Hu
Journal: Endoscopy (2021)

Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a first choice for acquiring samples from a pancreatic lesion [1]. However, due to the heterogeneity of the tumor, inaccurate localization of the positive puncture site will lead to a missed diagnosis The combination of contrast-enhanced harmonic endoscopic ultrasound and EUS-FNA can help to avoid puncture in necrotic areas, thus improving the diagnostic rate [2]. Unfortunately, the naked eye is not reliable for identifying and differentiating the targeted puncture sites suggested by contrast-enhanced harmonic EUS.
592P Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC)
Authors: M. Schweizer, R. Gulati, T. Yezefski, H. Cheng, C. Sievers, R. Dumpit, K. Alexander, N. McDonald, M. Lai, K. Nega, J. Hammond, P. Grivas, A. Hsieh, B. Montgomery, P. Nelson, E. Yu
Journal: Annals of Oncology (2021)
1157P Diagnostic therapeutic pathway (DTP) of early stage non-small cell lung cancer (eNSCLC): A real-world focus on EGFR status detection in resected patients (pts)
Authors: G. Pasello, M. Lorenzi, G. Pretelli, F. Pezzuto, G. Comacchio, A. Buja, L. Bonanno, V. Guarneri, P.F. Conte, F. Rea, F. Calabrese
Journal: Annals of Oncology (2021)
587P Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide)
Authors: A.K. Morgans, T.E. Hutson, A.K. Guan, D. Garcia, A. Zhou, E.J. Drea, N.J. Vogelzang
Journal: Annals of Oncology (2021)
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations
Authors: Maximilian J. Mair, Julia M. Berger, Anna S. Berghoff, Angelika M. Starzer, Gregor Ortmayr, Hannah C. Puhr, Ariane Steindl, Thomas Perkmann, Helmuth Haslacher, Robert Strassl, Selma Tobudic, Wolfgang W. Lamm, Markus Raderer, Manfred Mitterer, Thorsten Fuereder, Dominic Fong, Matthias Preusser
Journal: JAMA Oncology (2021)

To our knowledge, little is known about antibody development after SARS-CoV-2 vaccination in immunocompromised individuals, such as patients with cancer.To determine whether hematooncological patients develop anti-SARS-CoV-2 antibodies after vaccination.This retrospective cohort study included 2 independent cohorts of patients who were treated for hematological and solid malignant tumors between October 2020 and May 2021, comprising 901 samples from 595 patients and 58 health care workers (HCWs). Serum samples were collected from patients who were treated at an academic center and a community hospital in a rural area and a control group of HCWs, all of whom received SARS-CoV-2 vaccination.Total anti-SARS-CoV-2 nucleocapsid (anti-NC) and antispike protein (anti-S) antibodies were measured retrospectively.In total, 595 patients (320 women [53.8%] and 275 men [46.2%]; median [range] age, 67 [19-96] years) and 58 HCWs (40 women [69.0%] and 18 men [31.0%]; median [range] age, 42 [24-60] years) were included. Previous SARS-CoV-2 infection was documented in 43 of 595 (7.2%), while anti-NC antibodies that suggested previous infections were observed in 49 of 573 evaluable patients (8.6%). In both cohorts, anti-S antibody levels were higher in fully vaccinated patients compared with patients who received 1 dose. After the first vaccination, patients with hematological cancer who received B cell-targeting agents had lower anti-S levels (median, 1.6 AU/mL; range: 0-17 244 AU/mL) than patients who received other therapies (median, 191.6 AU/mL; range, 0-40 000; P < .001) or patients with solid tumors (median, 246.4 AU/mL; range, 0-40 000 AU/mL; P < .001). Anti-S levels after the first vaccination differed according to ongoing antineoplastic treatment modalities, with the lowest median levels in patients who received chemotherapy alone (157.7 AU/mL; range, 0-40 000 AU/mL) or in combination with immunotherapy (118.7 AU/mL; range, 14.1-38 727 AU/mL) and the highest levels in patients with no ongoing antineoplastic treatment (median, 634.3 AU/mL; range, 0-40 000 AU/mL; P = .01). Antibody levels after full immunization were higher in HCWs (median, 2500 U/mL; range, 485-2500 U/mL) than in patients with cancer (median, 117.0 U/mL; range, 0-2500 U/mL; P < .001).In this cohort study of patients with hematooncological diseases and a control group of HCWs, anti-SARS-CoV-2 antibodies after vaccination could be detected in patients with cancer. Lower antibody levels compared with HCWs and differences in seroconversion in specific subgroups underscore the need for further studies on SARS-CoV-2 vaccination in patients with hematooncological disease.
Government promises 40 new diagnostic centres to tackle backlog
Authors: Elisabeth Mahase
Journal: BMJ (2021)

The government has pledged £350m (€410m; $470m) to set up 40 new “one-stop-shops for checks, scans, and tests” as part of plans to tackle the NHS care backlog in England.1

The community based diagnostic centres, which could open in places such as shopping centres and football stadiums, will provide around 2.8 million scans in their first year of operation. They will be staffed by multidisciplinary teams seven days a week, and GPs will be able to refer patients to the hubs, the announcement said.

It said that the centres will start providing services over the next six months and will be fully operational by March 2022. However, with professional bodies warning of workforce shortages and no …
A cross-population atlas of genetic associations for 220 human phenotypes
Authors: Saori Sakaue, Masahiro Kanai, Yosuke Tanigawa, Juha Karjalainen, Mitja Kurki, Seizo Koshiba, Akira Narita, Takahiro Konuma, Kenichi Yamamoto, Masato Akiyama, Kazuyoshi Ishigaki, Akari Suzuki, Ken Suzuki, Wataru Obara, Ken Yamaji, Kazuhisa Takahashi, Satoshi Asai, Yasuo Takahashi, Takao Suzuki, Nobuaki Shinozaki, Hiroki Yamaguchi, Shiro Minami, Shigeo Murayama, Kozo Yoshimori, Satoshi Nagayama, Daisuke Obata, Masahiko Higashiyama, Akihide Masumoto, Yukihiro Koretsune, Kaoru Ito, Chikashi Terao, Toshimasa Yamauchi, Issei Komuro, Takashi Kadowaki, Gen Tamiya, Masayuki Yamamoto, Yusuke Nakamura, Michiaki Kubo, Yoshinori Murakami, Kazuhiko Yamamoto, Yoichiro Kamatani, Aarno Palotie, Manuel A. Rivas, Mark J. Daly, Koichi Matsuda, Yukinori Okada
Journal: Nature Genetics (2021)
924P HANNA: Effectiveness and quality-of-life data from a real-world study of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab in Germany
Authors: H. Müller-Huesmann, E. von der Heyde, D. Hahn, C. Langer, B. Kubuschok, U. Bockmühl, G. Klautke, P-S. Mauz, B. Reuter, D. Beutner, J. Büntzel, J. von der Grün, C-J. Busch, B. Tamaskovics, J. Riera-Knorrenschild, K. Gutsche, M. Welslau, T. Gauler, D. Waldenberger, A. Dietz
Journal: Annals of Oncology (2021)
New Insights on the Treatment of Colorectal Peritoneal Metastases From the CAIRO6 Trial—Reply
Authors: Koen P. Rovers, Checca Bakkers, Ignace H. J. T. de Hingh
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
344MO Experience of GEINO (Spanish cooperative group for research in neuro-oncology) oncologists in the management of adult medulloblastoma
Authors: M. Vieito Villar, R. Luque Caro, M.C. Martin Soberon, A. Herrero Ibañez, R. Girones Sarrio, N. Luque Caro, M. Alonso Garcia, T. Quintanar Verduguez, S. del Barco Berrón, I. Moya Horno, M.T. Tuñón Cabeza, O. Gallego, R. de las Peñas, M.Á. Vaz Salgado, I. Ceballos Lenza, A.J. Cunquero-Tomás, S. Peralta Muñoz, M. Gutierrez Toribio, J. Diaz Santos
Journal: Annals of Oncology (2021)
The UK should take the lead in pushing for reform of WHO, MPs say
Authors: Ingrid Torjesen
Journal: BMJ (2021)

The covid-19 pandemic put a spotlight on the “shortcomings” of the World Health Organisation, highlighting its lack of the funds, power, and independence to respond appropriately, a report by the House of Commons Foreign Affairs Committee has said.1

Almost echoing the view of former US president Donald Trump—who last year branded WHO “China-centric”2 then removed its US funding, further compromising WHO’s ability to act during the height of the pandemic3—the committee said that WHO “fell short on demanding transparency from Beijing, particularly in the early months, leading to costly delays in the international response.” …
397P R-IMMUNE interim analysis: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer
Authors: J. Carrasco, D. Schröder, I. Sinapi, A. De Cuyper, G. Beniuga, S. Delmarcelle, J-L. van Laethem, N. Huyghe, I. Bar, A. Hendlisz, K.M. Haustermans, T. Delaunoit, J-C. Coche, G. Van Ooteghem, A-S. Boulanger, P. Baldin, M. Van den Eynde
Journal: Annals of Oncology (2021)
Mortality in Staphylococcus aureus bacteraemia remains high despite adherence to quality indicators: secondary analysis of a prospective cohort study
Authors: Rein Willekens, Mireia Puig-Asensio, Paula Suanzes, Nuria Fernández-Hidalgo, Maria N. Larrosa, Juan J. González-López, Dolors Rodríguez-Pardo, Carles Pigrau, Benito Almirante
Journal: Journal of Infection (2021)
Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors
Authors: Bevin Bhoyrul, Leila Asfour, Gerhard Lutz, Lorne Mitchell, Rebekka Jerjen, Rodney D. Sinclair, Susan Holmes, Iskander H. Chaudhry, Matthew J. Harries
Journal: JAMA Dermatology (2021)

<h3>Importance</h3> Alopecia induced by classic chemotherapy affects up to 65% of patients and is usually reversible. However, there are increasing reports of persistent chemotherapy-induced alopecia (pCIA), especially for patients treated with taxane-containing chemotherapy regimens. <h3>Objective</h3> To analyze the clinicopathologic characteristics and response to treatment of patients with pCIA after chemotherapy for breast cancer. <h3>Design, Setting, and Participants</h3> In this case series, a retrospective evaluation was performed of patients with a diagnosis of pCIA after chemotherapy for breast cancer in 4 specialist hair clinics from November 1, 2011, to February 29, 2020. <h3>Main Outcomes and Measures</h3> Clinical, trichoscopic, and histopathologic characteristics and treatment outcomes were analyzed. For patients who presented with diffuse alopecia or diffuse rarefaction of hair over the midfrontal scalp with widening of the central part line and preservation of the frontal hairline, the Sinclair scale (grades 1-5, where 1 indicates normal hair density and 5 indicates the most severe stage of hair loss, with little or no hair in the centroparietal region) was used to assess severity. <h3>Results</h3> One hundred patients (99 women [99%]; mean age at presentation, 54.0 years [range, 29.0-74.1 years]) were included. Most patients had diffuse nonscarring alopecia (n = 39), female pattern hair loss (n = 55), or male pattern hair loss (n = 6). Six patients developed cicatricial alopecia. Taxane-containing regimens were used for most patients (92 [92%]) and were associated with more severe alopecia than regimens that did not contain taxanes (median Sinclair grade, 4 [IQR, 3-5] vs 2 [IQR, 2-2.5];<i>P</i> &lt; .001). A total of 76 of 86 patients (88%) had trichoscopic signs indistinguishable from those of androgenetic alopecia. Of 18 patients who had biopsies, 14 had androgenetic alopecia–like features, 2 had cicatricial alopecia, and 2 had features of both. Both topical and oral minoxidil, sometimes combined with antiandrogen therapy, were associated with an improvement in hair density (median Sinclair grade, 4 [IQR, 3-5] before treatment vs 3 [IQR, 2-4] after treatment;<i>P</i> &lt; .001). <h3>Conclusions and Relevance</h3> This case series outlines previously unreported features of pCIA in patients with breast cancer, including a trichoscopic description. Cosmetically significant regrowth was achieved for a significant proportion of patients with topical or systemic treatments, suggesting that pCIA may be at least partly reversible.
517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
Authors: N. Cook, S. Blagden, J. Lopez, D. Sarker, A. Greystoke, N. Harris, F. Kazmi, A. Naderi, G. Nintos, A. Ortego Franco, R. Pihlak, R. Shinde, L. Goodwin, C. Phillips, J. Robertson, A. Saunders, C. Tilston, S. Woodcock, R. Plummer
Journal: Annals of Oncology (2021)
291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting
Authors: J-S. Frenel, A. Lusque, A. Mailliez, T. Bachelot, L. Uwer, M.A. Mouret Reynier, C. Levy, C. Jouannaud, A. Gonçalves, A. Patsouris, V.C. Dieras, M. Leheurteur, T. Petit, P.H. Cottu, J-M. Ferrero, O. Villacroux, V. D'Hondt, I. Desmoulins, S. Delaloge, O. De Calbiac
Journal: Annals of Oncology (2021)
P-176 A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04)
Authors: V. Sahai, A. Chang, O. Crysler, D. Zhen, S. Luther, M. Zalupski
Journal: Annals of Oncology (2021)
1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program
Authors: J.J. Grob, F. Aubin, L. Benmahammed-Bellagha, F. Brunet-Possenti, O. Dereure, C. Dutriaux, A-B. Duval-Modeste, F. Grange, C. Jarvis, N. Kramkimel, M-T. Leccia, L. Machet, N. Meyer, L. Mortier, E-M. Neidhardt, C. Robert, E. Scherrer, A. Spampinato, L. Verdoni, P. Saiag
Journal: Annals of Oncology (2021)
271P First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
Authors: Y. Guo, J. Xue, W. Peng, L. Xue, X. Ge, W. Zhao, W. Tang, W. Nian, Q. Li, S. Zhang, J. Sun, M. Li, F. Hausheer, C. Hu, J. Li
Journal: Annals of Oncology (2021)
Iran COVID-19 Immunological Study: Remarkable Level of Interleukin-6 in Iranian COVID-19 Hospitalized Patients
Authors: Abdolrahman Rostamian, Tooba Ghazanfari, Jalil Arabkheradmand, Maryam Edalatifard, Sara Ghaffarpour, mohammad reza salehi, Seyed Reza Raeeskarami, Maedeh Mahmoodi Aliabadi, Maryam Rajabnia Chenary, Ensie Sadat Mirsharif, Davoud Jamali, Mohammad Reza Sattarian, Sajjad Hosseinieselki Sari, Samira Jafarpour, Reza Najafizadeh, Mohammad Mehdi Naghizadeh
Journal: The Lancet Respiratory Medicine (2020)
Mapping and modeling the genomic basis of differential RNA isoform expression at single-cell resolution with LR-Split-seq
Authors: Elisabeth Rebboah, Fairlie Reese, Katherine Williams, Gabriela Balderrama-Gutierrez, Cassandra McGill, Diane Trout, Isaryhia Rodriguez, Heidi Liang, Barbara J. Wold, Ali Mortazavi
Journal: Genome biology (2021)

Abstract The rise in throughput and quality of long-read sequencing should allow unambiguous identification of full-length transcript isoforms. However, its application to single-cell RNA-seq has been limited by throughput and expense. Here we develop and characterize long-read Split-seq (LR-Split-seq), which uses combinatorial barcoding to sequence single cells with long reads. Applied to the C2C12 myogenic system, LR-split-seq associates isoforms to cell types with relative economy and design flexibility. We find widespread evidence of changing isoform expression during differentiation including alternative transcription start sites (TSS) and/or alternative internal exon usage. LR-Split-seq provides an affordable method for identifying cluster-specific isoforms in single cells.